Combined Letrozole and Clomid in Women With Infertility and PCOS

Infertility Clinical Trial

Official title:

Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02802865
• Other study ID #: 201606806
• Status: Completed
• Phase: Phase 4
• Start date: August 2016
• Est. completion date: February 2019

Study information

• Verified date: September 2019
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the addition of clomid to letrozole for the treatment of infertility in women with polycystic ovary syndrome. Half of the participants will receive letrozole and clomid in combination, while the other half will receive letrozole alone.

Description:

Letrozole and Clomid are both used for ovulation induction, but they have different mechanisms of action. Letrozole has been shown to be superior to clomid in achieving live birth rates in women with infertility and polycystic ovary syndrome. However, the combination of these medications has not been studied. This is a pilot study to evaluate if the combination treatment has improved efficacy as measured by ovulation rate.

This is a randomized controlled trial of letrozole versus letrozole and clomiphene citrate (CC) for one menstrual cycle. Women will be randomized in a 1:1 ratio to receive letrozole 2.5 mg or combination of letrozole 2.5 mg and clomiphene 50 mg for 5 days on days 3-7 of menstrual cycle. The women and their partners will be instructed to have regular intercourse with the intent to conceive during the cycle. Patients will have an transvaginal ultrasound mid cycle and to evaluate number of follicles (>15 mm), follicle size, endometrial thickness and pattern. Patients will have mid- luteal phase progesterone level drawn to evaluate ovulation. Side effect profile will also be monitored.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: February 2019
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Willing to comply with all study procedures and be available for the duration of the study

2. Diagnosis of infertility: Inability of couple to achieve successful pregnancy after 12 months of regular timed unprotected intercourse in women less than 35 years of age; and after 6 months of regular intercourse without use of contraception in women 35 years and older

3. Diagnosis of polycystic ovary syndrome based on Revised Rotterdam criteria

4. Ability to have regular intercourse during the ovulation induction phase of the study

5. Normal sperm concentration of 15 million/mL and with normal motility of > 40% according to World Health Organization cutoff points, in at least one ejaculate during the previous year

Exclusion Criteria:

1. Current pregnancy

2. Current use of hormonal contraception; use of any type of combined contraceptive or oral progestins within the past month; or use of hormonal implants or depo progestins within the past 3 months

3. Other known cause of infertility: endometriosis, tubal factor, uterine abnormalities

4. Uncorrected thyroid disease

5. Untreated hyperprolactinemia.

6. Medical conditions in which avoiding pregnancy is recommended until under improved control: poorly controlled Type 1 or Type 2 diabetes, poorly controlled hypertension

7. Contraindications to clomiphene citrate: hypersensitivity to CC or any of its components, history of liver disease or known liver disease, unknown cause of abnormal uterine bleeding, or intracranial lesion

8. Contraindications to letrozole: hypersensitivity to letrozole or any of its components.

9. Use of medications known to affect reproductive function or metabolism or that are an absolute contraindication during pregnancy within the past month.

10. If patients are suspected based on clinical findings for other etiologies that mimic PCOS, work up must be completed to exclude other etiologies prior to enrollment (i.e. Cushing's syndrome, androgen-secreting tumor).

Related Conditions & MeSH terms

• Infertility
• Polycystic Ovary Syndrome
• Syndrome

Intervention

Drug:
• Clomiphene

• Letrozole

Locations

Country	Name	City	State
United States	University of Iowa Hospitals & Clinics	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Rachel Mejia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level	Ovulation: mid-luteal progesterone > /=3 ng/mL. No ovulation: mid-luteal progesterone <3ng/mL.	7 days following LH surge or at cycle day 21 if no LH surge was detected
Secondary	Number of Developing Follicles	Number of follicles measuring > 10mm on ultrasound	Cycle day 12-14
Secondary	Size of Largest Developing Follicle	Size of largest follicle on ultrasound	Cycle day 12-14
Secondary	Endometrial Thickness	Thickness of endometrial lining assessed by ultrasound	Cycle day 12-14
Secondary	Conception	Conception: a positive serum or urinary test of hCG; No conception: Neither a positive serum or urinary test of hCG	5 weeks after treatment
Secondary	Clinical Pregnancy	Clinical Pregnancy: an intrauterine pregnancy with fetal heart motion determined by ultrasonography; No Clinical Pregnancy: no intrauterine pregnancy with fetal heart motion determined by ultrasonography	6-7 weeks after treatment
Secondary	Multiple Gestation	Multiple Gestation: an intrauterine pregnancy with multiple fetal heart rates determined by ultrasonography; No Multiple Gestation: either no intrauterine pregnancy, or an intrauterine pregnancy with a single fetal heart rate determined by ultrasonography	9-10 months after treatment
Secondary	Live Birth	Live Birth: delivery of a live infant; No Live Birth: no delivery of a live infant	9-10 months after treatment
Secondary	Pregnancy Loss	Pregnancy Loss: any pregnancy loss including biochemical pregnancy, ectopic pregnancy, and miscarriage; No Pregnancy Loss: no pregnancy loss including biochemical pregnancy, ectopic pregnancy, or miscarriage.	9-10 months after treatment